Kirkland & Ellis is advising global biopharmaceutical company Bristol Myers Squibb (NYSE: BMY) on the acquisition of commercial stage research and development biotechnology company Mirati Therapeutics (NASDAQ:MRTX). The transaction was announced October 8, 2023. The deal has been unanimously approved by both the Bristol Myers Squibb and Mirati boards of directors. Bristol Myers Squibb has […]
The post Kirkland Advises Bristol Myers Squibb on Acquisition of Mirati Therapeutics for up to $5.8 Billion appeared first on Legal Desire Media and Insights.